Fundamental study on molecular target therapy in oral cancer patients with cetuximab resistance
| Project/Area Number |
15K20544
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Nagasaki University |
|---|
Principal Investigator |
NARUSE Tomofumi 長崎大学, 医歯薬学総合研究科(歯学系), 助教 (70549609)
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | セツキシマブ / mTOR / PI3Kp110α / Resistance / mTOR阻害薬 / セツキシマブ耐性 / EGFR / 口腔扁平上皮癌 / PIK3CA遺伝子 |
|---|
| Outline of Final Research Achievements |
① In 17 patients who were able to collect the excised tissue just before the cetuximab administration, the expression of PI3Kp110α, a subunit of PIK3CA, showed a significant correlation with the treatment outcome. In 1- year progressive survival rate, survival rate was decreased in cases with overexpression.
② Three oral cancer cell lines were used to calculate proliferative index and invasive index by MTT assay and Invasion assay. Western blot analysis was performed because of association with the expression of PI3Kp110α, and as a result, there was a significant correlation with invasive index. In addition, we examined the correlation with Cetuximab IC50 and found that there was no significant difference, but a certain tendency was observed in susceptibility depending on the strength of expression.
|
Report
(3 results)
Research Products
(10 results)
